Sugi Predict

Sugi Predict / Compounds / SCHEMBL4131575

SCHEMBL4131575

SCHEMBL4131575

Cc1ccc(S(=O)(=O)OC2CCC(F)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 2/20 0.58
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 3/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA3 P07451 1/20 0.41
▸ CA6 P23280 1/20 0.41
▸ CA5A P35218 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ CA5B Q9Y2D0 1/20 0.41
▸ GAA P10253 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ CYP2C9 P11712 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ ACHE P22303 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25171077 1.00 CYP2D6 (0.58) CYP2D6CYP1A2CYP3A4CYP2C19CA12
SCHEMBL10376015 0.91 CYP2D6 (0.67) CYP2D6CYP1A2CYP3A4CYP2C19CA12
SCHEMBL657896 0.91 CYP2D6 (0.67) CYP2D6CYP1A2CYP3A4CYP2C19CA12
SCHEMBL9365925 0.85 CYP2D6 (0.60) CYP2D6CYP1A2CYP3A4CYP2C19CA12
SCHEMBL11939929 0.85 CYP2D6 (0.52) CYP2D6CYP1A2CYP3A4CYP2C19CA12
SCHEMBL10725343 0.85 CYP2D6 (0.60) CYP2D6CYP1A2CYP3A4CYP2C19CA12
SCHEMBL1042376 0.85 CYP2D6 (0.52) CYP2D6CYP1A2CYP3A4CYP2C19CA12
SCHEMBL1042377 0.85 CYP2D6 (0.52) CYP2D6CYP1A2CYP3A4CYP2C19CA12
SCHEMBL9365920 0.85 CYP2D6 (0.60) CYP2D6CYP1A2CYP3A4CYP2C19CA12
SCHEMBL777214 0.84 CYP2D6 (0.63) CYP2D6CYP1A2CYP3A4CYP2C19CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024218296-A1 COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS H. LUNDBECK A/S (DK) 2024-10-24 — — WO disclosed
US-12100809-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-24 — — US disclosed
EP-4422750-A1 LRRK2 INHIBITORS H. Lundbeck A/S (DK) 2024-09-04 — — EP disclosed
CN-118251397-A LRRK2 inhibitors H.隆德贝克有限公司 2024-06-25 — — CN disclosed
US-11993612-B2 LRRK2 inhibitors H. LUNDBECK A/S (DK) 2024-05-28 — — US disclosed
US-20230416272-A1 LRRK2 INHIBITORS H. LUNDBECK A/S (DK) 2023-12-28 — — US disclosed
US-11780851-B2 LRRK2 inhibitors H. LUNDBECK A/S (DK) 2023-10-10 — — US disclosed
WO-2023073013-A9 LRRK2 INHIBITORS H. LUNDBECK A/S (DK) 2023-08-17 — — WO disclosed
US-20230144725-A1 LRRK2 INHIBITORS H. LUNDBECK A/S (DK) 2023-05-11 — — US disclosed
WO-2023073013-A1 LRRK2 INHIBITORS H. LUNDBECK A/S (DK) 2023-05-04 — — WO disclosed
US-11283107-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2022-03-22 — — US disclosed
EP-3621141-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2020-03-11 — — EP disclosed
US-20190229372-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2019-07-25 — — US disclosed
US-10333172-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2019-06-25 — — US disclosed
US-10290901-B2 — — 2019-05-14 — — US disclosed
US-9608291-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2017-03-28 — — US disclosed
US-20170084955-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2017-03-23 — — US disclosed
US-20150188192-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2015-07-02 — — US disclosed
US-20150056503-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2015-02-26 — — US disclosed
EP-2012386-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY Mitsubishi Chemical Corporation (JP) 2009-01-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11993612-B2 LRRK2 inhibitors LRRK2, PARK7, PINK1 CYP2D6 3478/4885CYP1A2 4261/4885CYP3A4 4618/4885
US-11780851-B2 LRRK2 inhibitors LRRK2, PARK7, PINK1 CYP2D6 3478/4885CYP1A2 4261/4885CYP3A4 4618/4885
US-20230416272-A1 LRRK2 INHIBITORS LRRK2, PARK7, PINK1 CYP2D6 3478/4885CYP1A2 4261/4885CYP3A4 4618/4885
US-20230144725-A1 LRRK2 INHIBITORS LRRK2, PARK7, PINK1 CYP2D6 3478/4885CYP1A2 4261/4885CYP3A4 4618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.